Supreme to Trade on the Canadian Securities Exchange

C.SL

CALGARY, ALBERTA--(Marketwired - April 21, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWF) (CSE:SL) announces that the Company is moving its listing from the TSX Venture Exchange to the Canadian Securities Exchange (CSE, formerly the CNSX) today under the symbol SL. This move will allow the efficient and seamless transition from a junior resource company to one whose main focus is now on the emerging medical marijuana field. 

The Company also clarifies its April 15, 2014 cancellation of its planned financing, which became unnecessary due to exercises to date of outstanding warrants in excess of $1,000,000. Proceeds from the warrants exercises exceeded the proposed financing and management wish to avoid additional dilution.

President and CEO, David Stadnyk stated: "While we have longstanding relationships with both the TSX Venture and the Canadian Securities Exchange, we believe this is the right move for the Company at this time. We now have two producing medical marijuana facilities under evaluation and expect to report positive news shortly."

SUPREME PHARMACEUTICALS INC.

David StadnykPresident & CEO

FORWARD LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
David Stadnyk
President & CEO
(647) 340-6744
info@supremepharmaceuticals.com

Supreme Pharmaceuticals Inc.
430 - 580 Hornby Street, Vancouver BC
V6C 3B6
www.supremepharmaceuticals.com


Rate this press release
3 stars
v
Usefulness

Clarity

Credibility
Add to favourites icon Add to favourites